Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Chemical Research in Toxicology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/TX034170BPMID 14727914
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins.

  2003cited by this paper
• Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques.

  2003cited by this paper
• The anticonvulsant hypersensitivity syndrome

  2003cited by this paper
• Sequence Mapping of Epoxide Adducts in Human Hemoglobin with LC−Tandem MS and the Salsa Algorithm

  2002cited by this paper
• Sequence mapping of epoxide adducts in human hemoglobin with LC-tandem MS and the SALSA algorithm.

  2002cited by this paper
• Timing of new black box warnings and withdrawals for prescription medications.

  2002cited by this paper
• Identification of seven proteins in the endoplasmic reticulum as targets for reactive metabolites of bromobenzene.

  2002cited by this paper
• Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.

  2002cited by this paper
• On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics.

  2002cited by this paper
• Reactive intermediates and the dynamics of glutathione transferases.

  2002cited by this paper
• Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humans.

  2001cited by this paper
• Metabolism of fluorine-containing drugs.

  2001cited by this paper
• Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

  2001cited by this paper
• Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.

  2001cited by this paper
• Immunological Principles of Adverse Drug Reactions

  2000cited by this paper
• 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides.

  2000cited by this paper
• Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation.

  2000cited by this paper
• Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone.

  2000cited by this paper
• Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac.

  1999cited by this paper
• Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.

  1999cited by this paper
• New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system.

  1999influential reference
• Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins.

  1999cited by this paper
• Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites.

  1999cited by this paper
• (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6.

  1998cited by this paper
• Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective.

  1998cited by this paper
• A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo.

  1998cited by this paper
• Alkylation of 2'-deoxynucleosides and DNA by the Premarin metabolite 4-hydroxyequilenin semiquinone radical.

  1998cited by this paper
• Identification of the Hepatic Protein Targets of Reactive Metabolites of Acetaminophen in Vivo in Mice Using Two-dimensional Gel Electrophoresis and Mass Spectrometry*

  1998cited by this paper
• Protein targets of xenobiotic reactive intermediates.

  1997cited by this paper
• Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis.

  1997cited by this paper
• Selective protein covalent binding and target organ toxicity.

  1997cited by this paper
• Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.

  1997cited by this paper
• Erratum: Characterisation of the toxic metabolite(s) of naphthalene (Toxicology 114 (1996) (233)) PII S0300483X96035159

  1997cited by this paper
• Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.

  1997cited by this paper
• Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.

  1997cited by this paper
• Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia.

  1997cited by this paper
• Protein targets of xenobiotic reactive intermediates.

  1997influential reference
• Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates.

  1996cited by this paper
• In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4.

  1996cited by this paper
• Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: evidence for furan bioactivation.

  1996cited by this paper
• Characterisation of the toxic metabolite(s) of naphthalene.

  1996cited by this paper
• Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes.

  1996cited by this paper
• Protein-reactive metabolites of carbamazepine in mouse liver microsomes.

  1996cited by this paper
• Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate.

  1996cited by this paper
• Microsomal metabolism of the 5-lipoxygenase inhibitors L-746,530 and L-739,010 to reactive intermediates that covalently bind to protein: the role of the 6,8-dioxabicyclo[3.2.1]octanyl moiety.

  1995cited by this paper
• Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine.

  1995cited by this paper
• Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin.

  1995cited by this paper
• Mechanisms of acetaminophen toxicity: immunochemical detection of drug-protein adducts.

  1995cited by this paper
• Anticonvulsant hypersensitivity syndrome.

  1995cited by this paper
• The metabolism of alicyclic amines to reactive iminium ion intermediates

  1994cited by this paper
• Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis.

  1994cited by this paper
• Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct.

  1994cited by this paper
• Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications.

  1994cited by this paper
• Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac: radiochemical and immunochemical analysis.

  1994cited by this paper
• Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs.

  1994cited by this paper
• Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

  1993cited by this paper
• Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes.

  1993cited by this paper
• Correlation of metabolism, covalent binding and toxicity for a series of bromobenzene derivatives using rat liver slices in vitro.

  1993cited by this paper
• Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac.

  1993cited by this paper
• Mass spectrometry in the analysis of glutathione conjugates.

  1993cited by this paper
• Identification of a cysteinyl adduct of oxidized 3-methylindole from goat lung and human liver microsomal proteins.

  1992cited by this paper
• The mechanism of bioactivation and antigen formation of amodiaquine in the rat.

  1992cited by this paper
• Agranlocytosis caused by ticlopindine and its mechanism

  1991cited by this paper
• Metabolism of 3-methylindole in human tissues.

  1991cited by this paper
• Trapping of reactive intermediates by incorporation of 14C-sodium cyanide during microsomal oxidation.

  1991cited by this paper
• Agranulocytosis caused by ticlopidine and its mechanism.

  1991cited by this paper
• Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system

  1990cited by this paper
• Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism.

  1990cited by this paper
• Mechanisms of 3-methylindole pneumotoxicity.

  1989cited by this paper
• Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver.

  1989cited by this paper
• The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes.

  1989cited by this paper
• Selective acetaminophen metabolite binding to hepatic and extrahepatic proteins: an in vivo and in vitro analysis.

  1989cited by this paper
• Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.

  1988cited by this paper
• Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice.

  1988cited by this paper
• Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid.

  1988influential reference
• Immediate hypersensitivity reactions to penicillin and related antibiotics

  1988cited by this paper
• In Vitro Assessment of Risk

  1988cited by this paper
• In vitro metabolism and covalent binding among ortho-substituted bromobenzenes of varying hepatotoxicity.

  1988cited by this paper
• Species-dependent enantioselective glucuronidation of three 2-arylpropionic acids. Naproxen, ibuprofen, and benoxaprofen.

  1987cited by this paper
• Stereoselectivity of naphthalene epoxidation by mouse, rat, and hamster pulmonary, hepatic, and renal microsomal enzymes.

  1987cited by this paper
• Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers.

  1987cited by this paper
• Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982.

  1986cited by this paper
• Characterization of the isomeric esters of zomepirac glucuronide by proton NMR.

  1986cited by this paper
• Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982.

  1986cited by this paper
• Covalent binding of the phenacetin metabolite p-nitrosophenetole to protein.

  1986cited by this paper
• Irreversible binding of zomepirac to plasma protein in vitro and in vivo.

  1986cited by this paper
• Glutathione conjugates of 2-bromohydroquinone are nephrotoxic.

  1985cited by this paper
• Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes.

  1985cited by this paper
• Drug protein conjugates--III. Inhibition of the irreversible binding of ethinylestradiol to rat liver microsomal protein by mixed-function oxidase inhibitors, ascorbic acid and thiols.

  1983cited by this paper
• Drug-protein conjugates--II. An investigation of the irreversible binding and metabolism of 17 alpha-ethinyl estradiol in vivo.

  1983cited by this paper
• Effect of a 6-fluoro substituent on the metabolism and biological activity of benzo(a)pyrene.

  1983cited by this paper
• The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans.

  1982cited by this paper
• The biotransformation of 17 alpha-ethynyl[3H]estradiol in the rat: irreversible binding and biliary metabolites.

  1982cited by this paper
• Practolol metabolism. III. Irreversible binding of [14C]practolol metabolite(s) to mammalian liver microsomes.

  1981cited by this paper
• Comparison of ratios of covalent binding to total metabolism of the pulmonary toxin, 4-ipomeanol, in vitro in pulmonary and hepatic microsomes, and the effects of pretreatments with phenobarbital or 3-methylcholanthrene.

  1980cited by this paper
• Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine.

  1978cited by this paper
• In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol.

  1978cited by this paper
• Hepatic sensitivity to imipramine

  1977cited by this paper
• Metabolic Activation of Hydrazines to Highly Reactive Hepatotoxic Intermediates

  1977cited by this paper
• Physicians Desk Reference (PDR)

  1977cited by this paper

• Discovery of 1-(Azetidin-3-ylmethyl)-1H-benzo[d]imidazole Derivatives as Efficient GSTP1 Inhibitors for Gastric Cancer Treatment via Warhead Removal Strategy.

  2026cites this paper
• Metabolic Stability of Fluorinated Small Molecules: A Physical Organic Chemistry Perspective.

  2026cites this paper
• Relevance of Reactive Metabolites and Covalent Binding to Drug Candidate Selection.

  2026cites this paper
• Proceedings of the 2024 Classic Examples in Toxicologic Pathology XXXI.

  2025cites this paper
• In-depth understanding of the structure-based reactive metabolite formation of organic functional groups

  2025cites this paper
• The covalent docking software landscape: features and applications in drug design

  2025cites this paper
• Drug‐Induced Liver Injury Associated With Emerging Cancer Therapies

  2025cites this paper
• Assessment of liver injury potential of investigational medicines in drug development.

  2025cites this paper
• In Situ Electrochemical Synthesis of Redox-Active o-Hydroquinone Metabolite of Flufenamic Acid on MWCNT Surface: Lifespan Extension in C. elegans via SOD Pathway.

  2025cites this paper
• DILI prediction in drug development: present and future

  2025cites this paper
• Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy

  2025cites this paper
• Covalent drug – An emerging framework for targeted drug development

  2024cites this paper
• A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.

  2024cites this paper
• A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology

  2024cites this paper
• Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure.

  2024cites this paper
• Cyanide Trapping of Iminium Ion Reactive Metabolites: Implications for Clinical Hepatotoxicity.

  2024cites this paper
• Bioactivation and reactivity research advances – 2023 year in review

  2024cites this paper
• Electrochemical Oxidative Degradation and Trapping of the Mefenamic Acid Drug as a Redox-Active Hydroxy Metabolite on a Carbon Black Surface: Mediated Oxidation and Sensing of Thiol Biomarker

  2024cites this paper
• Development of a fluorous trapping reagent for rapid detection of electrophilic reactive metabolites.

  2024cites this paper
• Detection and Quantification of Drug–Protein Adducts in Human Liver

  2024cites this paper
• The skin sensitization adverse outcome pathway: exploring the role of mechanistic understanding for higher tier risk assessment

  2024cites this paper
• Mechanistic Investigation of the Time-Dependent Aldehyde Oxidase Inhibitor Hydralazine

  2023cites this paper
• A MIST conception: what has been learned from twenty years of human metabolite safety assessment?

  2023cites this paper
• Green electrosynthesis of drug metabolites

  2023cites this paper
• Acyl glucuronides–mediators of drug-induced toxicities?

  2023cites this paper
• Preclinical evaluation of chemically reactive metabolites and mitigation of bioactivation in drug discovery.

  2023cites this paper
• What’s been Hapten-ing over the last 88 years?

  2023cites this paper
• Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat.

  2023cites this paper
• Rhenium(V) Complexes as Cysteine-Targeting Coordinate Covalent Warheads

  2023cites this paper
• Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI

  2023cites this paper
• Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification.

  2022cites this paper
• Idiosyncratic Drug Reactions: A 35-Year Chemical Research in Toxicology Perspective

  2022cites this paper
• Why 90% of clinical drug development fails and how to improve it?

  2022cites this paper
• Amino Alcohols as Potential Antibiotic and Antifungal Leads

  2022cites this paper
• Computational Investigation of the Bisphenolic Drug Metabolism by Cytochrome P450: What Factors Favor Intramolecular Phenol Coupling.

  2022cites this paper
• ADME Principles in Small Molecule Drug Discovery and Development: An Industrial Perspective

  2022cites this paper
• Roles of cytochrome P450 enzymes in pharmacology and toxicology: Past, present, and future.

  2022cites this paper
• Factors influencing drug toxicity

  2022cites this paper
• In Silico ADMET Analysis of the A-, B- and D-modified Androstane Derivatives with Potential Anticancer Effects.

  2022cites this paper
• The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions

  2021cites this paper
• Effects of Dufulin on Oxidative Stress and Metabolomic Profile of Tubifex

  2021cites this paper
• Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitor

  2021influential citation
• Novel advances in biotransformation and bioactivation research – 2020 year in review

  2021cites this paper
• Discovery of Covalent Drugs Targeting the Key Enzymes of SARS-CoV-2 Using SCARdock

  2021cites this paper
• Development of fluorescent-labeled trapping reagents based on cysteine to detect soft and hard electrophilic reactive metabolites.

  2021cites this paper
• Cell-based high-throughput screening for the evaluation of reactive metabolite formation potential.

  2021cites this paper
• Identification and characterization of in vitro, in vivo, and reactive metabolites of tandutinib using liquid chromatography ion trap mass spectrometry.

  2021cites this paper
• Modeling the Bioactivation and Subsequent Reactivity of Drugs.

  2021cites this paper
• In-Vitro Approaches to Predict and Study T-Cell Mediated Hypersensitivity to Drugs

  2021cites this paper
• Discovery and Visualization of Uncharacterized Drug–Protein Adducts Using Mass Spectrometry

  2021cites this paper
• On the Origin of the Different Reversible Characters of Salinosporamide A and Homosalinosporamide A in the Covalent Inhibition of the Human 20S Proteasome

  2021cites this paper
• Metabolite Profiling of Meridianin C In Vivo of Rat by UHPLC/Q-TOF MS

  2021cites this paper
• Cytochrome P450-Mediated Drug Bioactivation Assay: An Untargeted High Resolution Accurate Mass LC/MS Assay

  2021cites this paper
• Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges

  2021cites this paper
• Permeabilized Cryopreserved Human Hepatocytes as an Exogenous Metabolic System in a Novel Metabolism-Dependent Cytotoxicity Assay for the Evaluation of Metabolic Activation and Detoxification of Drugs Associated with Drug-Induced Liver Injuries: Results with Acetaminophen, Amiodarone, Cyclophosphami

  2021cites this paper
• Liquid Chromatography‐Mass Spectrometry (LC‐MS) Quantification of Reactive Metabolites

  2021cites this paper
• Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione.

  2021cites this paper
• Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy

  2021cites this paper
• Transporter, Drug Metabolism, and Drug‐Induced Liver Injury in Marketed Drugs

  2021cites this paper
• Comprehensive in vitro metabolism study of bisphenol A using liquid chromatography-high resolution tandem mass spectrometry.

  2020cites this paper
• Reactive Metabolites: Generation and Estimation with Electrochemistry Based Analytical Strategy as an Emerging Screening Tool

  2020cites this paper
• Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites

  2020cites this paper
• Synergy between Experiments and Computations: A Green Channel for Revealing Metabolic Mechanism of Xenobiotics in Chemical Toxicology.

  2020cites this paper
• Organ-Specific Screening for Protein Damage Using Magnetic Bead Bioreactors and LC-MS/MS.

  2020cites this paper
• EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: In Vivo and In Vitro Rat Studies.

  2020cites this paper
• Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation

  2020cites this paper
• Progress of derisking strategies for drug-induced liver injury (DILI) in the last two decades

  2020cites this paper
• Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics

  2020cites this paper
• Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.

  2020cites this paper
• Approaches to mitigate the risk of serious adverse reactions in covalent drug design

  2020cites this paper
• Site-Level Bioactivity of Small-Molecules from Deep-Learned Representations of Quantum Chemistry.

  2020cites this paper
• Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach

  2020cites this paper
• Designing Around Structural Alerts in Drug Discovery.

  2020cites this paper
• Stepwise Design of γ-Secretase Modulators with Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere.

  2020cites this paper
• A history of the roles of cytochrome P450 enzymes in the toxicity of drugs

  2020cites this paper
• Evaluation of covalent binding of flutamide and its risk assessment using 19F-NMR

  2020cites this paper
• Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites

  2020cites this paper
• XenoNet: Inference and Likelihood of Intermediate Metabolite Formation

  2020cites this paper
• Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib

  2020cites this paper
• Screening trimethoprim primary metabolites for covalent binding to albumin

  2020cites this paper
• Drug–protein adducts: past, present, and future

  2020cites this paper
• Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury

  2020influential citation
• Models of Idiosyncratic Drug-Induced Liver Injury.

  2020cites this paper
• Application of a fluorous derivatization method for characterization of glutathione-trapped reactive metabolites with liquid chromatography-tandem mass spectrometry analysis.

  2020cites this paper
• A high-throughput glutathione trapping assay with combined high sensitivity and specificity in high-resolution mass spectrometry by applying product ion extraction and data-dependent neutral loss.

  2019cites this paper
• Novel risk assessment of reactive metabolites from discovery to clinical stage.

  2019cites this paper
• Phase I and phase II metabolism simulation of antitumor-active 2-hydroxyacridinone with electrochemistry coupled on-line with mass spectrometry

  2019influential citation
• Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling

  2019cites this paper
• Application of cytochrome P450 reactivity on the characterization of chemical compounds and its association with repeated-dose toxicity.

  2019cites this paper
• Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo.

  2019cites this paper
• Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®.

  2019cites this paper
• Role of Oxidative Stress in Hypersensitivity Reactions to Sulfonamides

  2019cites this paper
• Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling

  2019cites this paper
• Enzalutamide and Apalutamide: In vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model.

  2019cites this paper
• The Journal of Toxicological Sciences

  2019cites this paper
• Applications of Reactive Cysteine Profiling.

  2019cites this paper
• Predicting Drug-Induced Liver Injury with Bayesian Machine Learning.

  2019cites this paper
• Liquid chromatography–tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites

  2019cites this paper
• Mechanistic Studies of Idiosyncratic DILI: Clinical Implications

  2019cites this paper
• Predicting the Risks of Drug-Induced Liver Injury in Humans Utilizing Computational Modeling

  2019cites this paper